Work

Current therapies and new developments in NASH

Year: 2022

Type: article

Abstract: Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.

Source: Gut

DOI: 10.1136/gutjnl-2021-326874

Authors: Jean-François Dufour, Quentin M Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai-Sun Wong, Shira Zelber-sagi

Institutions: Newcastle University, University of Turin, University of Oxford, Pinnacle Clinical Research, University of California San Diego, Hôpital Beaujon, Innsbruck Medical University, Universität Innsbruck, Chinese University of Hong Kong, Tel Aviv Sourasky Medical Center, University of Haifa

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Intercept Pharmaceuticals, Siemens Healthineers, National Institute on Alcohol Abuse and Alcoholism, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: G1316440902, G1370780335, G1494183008, G1622551803, G2323685147, G2928778974, Novel IL-23 inhibitor for the treatment of alcohol associated liver disease, G7198334374, G745677937, G7501542120, G7562742651, G8150884884, San Diego Digestive Diseases Research Center, San Diego Cirrhosis Clinical Research Network

OpenAlex ID: W4283011943

FWCI: 26.7

Cites: 128

Cited by: 191

Related to: 10